do glp 1 drugs reduce inflammation Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent A Comprehensive Review of the

Chiefari E, Capula C, Vero A, et al

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

GLP-1 receptor agonists have been shown to provide superior glycemic control and weight loss relative to the DPP-4 inhibitors

Triple agonists wont make dual agonists obsolete

Furthermore, it acts on the stomach and the brain to control gastric emptying and feelings of satiety, which aid in the management of metabolic risk factors that contribute to T2DM exacerbation

Till date though, its efficacy and safety has already been showcased in a randomized and parallel group trial, a study design associated with lower risk of bias and carry-over effects